Omontys and Drug hypersensitivity - a phase IV clinical study of FDA data

Summary:

Drug hypersensitivity is reported as a side effect among people who take Omontys (peginesatide acetate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Venofer, and have Nephrogenic anaemia.

The phase IV clinical study analyzes which people have Drug hypersensitivity when taking Omontys. It is created by eHealthMe based on reports of 203 people who have side effects when taking Omontys from the FDA, and is updated regularly.

What is Omontys?

Omontys has active ingredients of peginesatide acetate. eHealthMe is studying from 203 Omontys users. Check the latest studies of Omontys.

What is Drug hypersensitivity?

Drug hypersensitivity is found to be associated with 2,480 drugs and 2,340 conditions by eHealthMe. Check the latest studies of Drug hypersensitivity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

203 people reported to have side effects when taking Omontys.
Among them, 12 people (5.91%) have Drug hypersensitivity.

Could Omontys cause Drug hypersensitivity?

Among these 12 people:

How long have people been on Omontys when they have Drug hypersensitivity? *

What is the gender of people who have Drug hypersensitivity when taking Omontys? *

female: 83.33 %
male: 16.67 %

What is the age of people who have Drug hypersensitivity when taking Omontys? *

What are other drugs people take besides Omontys? *

What are other side effects people have besides Drug hypersensitivity? *

Nausea (feeling of having an urge to vomit): 5 people, 41.67%
Dyspnea (difficult or laboured breathing): 5 people, 41.67%
Lip Swelling: 4 people, 33.33%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 33.33%
Chest Pain: 4 people, 33.33%
Rashes (redness): 4 people, 33.33%
Urticaria (rash of round, red welts on the skin that itch intensely): 3 people, 25.00%
Itching: 3 people, 25.00%
Arrhythmias (irregular heartbeat): 2 people, 16.67%
Hypotension (abnormally low blood pressure): 2 people, 16.67%

What are the existing conditions these people have? *

Nephrogenic Anaemia (anaemia due to kidney disease): 11 people, 91.67%
Osteoporosis (bones weak and more likely to break): 1 person, 8.33%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 1 person, 8.33%
Chronic Kidney Disease: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Omontys and have Drug hypersensitivity?

- Check whether Drug hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Omontys:

Omontys (203 reports)

Browse all side effects of Omontys:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Drug hypersensitivity:

Drug hypersensitivity (2,480 drugs)

Browse all the conditions that are associated with Drug hypersensitivity:

Drug hypersensitivity (2,340 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on peginesatide acetate (the active ingredients of Omontys) and Omontys (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.